NCT00999882 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

CancerAdvanced Hepatocellular Carcinoma

Interventions

DRUG

AZD8055

Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.

Trial Locations (3)

Unknown

Research Site, Hong Kong

Research Site, Seongnam-si

Research Site, Seoul